Treating vascular risk factors and preventing Alzheimer's

Research and Practice in Alzheimer's Disease

Volumn 12, Issue , 2007, Pages 59-65

  Alagiakrishnan, Kannayiram ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b GLENROSE REHABILITATION HOSPITAL   (Canada)

Author keywords

Alzheimer's dementia; Prevention; Vascular factors

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; ASCORBIC ACID; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRENDIPINE; PERINDOPRIL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; SIMVASTATIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DRUG MECHANISM; EXERCISE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; PHYSICAL ACTIVITY; PRIMARY PREVENTION; RISK FACTOR; RISK REDUCTION; VASCULAR DISEASE; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; WALKING;

EID: 70349118087     PISSN: 12848360     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (35)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J Public Health 1998 Sep; 88(9): 1337-42.
2. Hofman A, Ott A, Breteler MMB, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet 1997; 349: 151-54.
3. Dela Torre JC. Vascular basis of Alzheimer's pathogenesis. Annals of the New York Academy of sciences 2002;977 :196-215.
4. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: The NUN study. JAMA 1997; 277: 813-7.
5. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease : inflammation, cholesterol and misfolded proteins. Lancet 2004; 363 : 1139-1146.
6. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65(4): 545-51.
7. Alagiakrishnan K, McCracken P, Feldman H. Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline? Postgrad Med J 2006; 82 (964) : 101-5.
8. Mila Kivipeito, Eeva-Liisa Helkala, Mikko P.Laakso, Tuomo Hanninen, Merja Hallikainen, Kari Alhainen et al. Apolipoprtein E4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late- life Alzheimer's disease. Ann Intern Med 2002; 137:149-155.
9. Laitinen MH, Ngandu T, Rovio S, et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. Dement Geriatr Cogn Disord. 2006; 22(1): 99-107.
10. Sudha Seshadri, Alexa Beiser, Jacob Selhub, Paul F. Jacques, Irwin H. Rosenberg, Ralph B. D'Agostino et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's Disease. N Engl J Med, Feb 14, 2002; Vol.346, No. 7:476-82.
11. Renvall M.J, Spindler A.A et al. Nutritional status of free-living Alzheimer's patients. Am J Med Sci 1989;298(1) : 20-7.
12. Serot J, Christmann D, et al.CSF folate levels are decreased in late -onset AD patients. J Neural Transm 2001;108(1) :93-9.
13. Skoog I, Lernfeldt B, Landahl S et al. 15- year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
14. Launer LJ, Ross GW, Petrovich H, et al. Midlife blood pressure and dementia:the Honolulu- Asia aging study. Neurobiol. Aging 2000;21(1):49-55.
15. Mila Kivipelto, Eeva-Liisa Helkala, Mikko P Laakso, Tuomo Hanninen, Merja Hallikaimen, Kari Alhainen, Hilkka Soininen, Jaakko Tuomilehto and Aulikki Nissimen. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal population based study. BMJ 2001; 322:1447-1451.
16. Shah RC, Wilson RS, Bienias JL et al. Relation of blood pressure to risk of incident Alzheimer's disease and change in global cognitive function in older persons. Neuroepidemiology 2006; 26(1): 30-36.
17. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.
18. Hanon O, Pequignot R, Seux ML et al. relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens 2006; 10: 2101-2107.
19. Ohrui T, Tomita N, Sato- Nakagawa T, et al. Effects of brain- penetrating ACE inhibitors on Alzheimer's disease progression. Neurology 2004; 63(7): 1324-25.
20. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer's disease. Arch Neurol. 2006; 63: 686-692.
21. McGuinness B, Todd S, Passmore P, Bullock R. The effects of blood pressure lowering on developing cognitive impairment and dementia in patients without prior cerebrovascular disease. Cochrane Database Syst rev 2006; (2): CD 004034.
22. Mila Kivipelto, Eeva-Liisa Helkala, Mikko P Laakso, Tuomo Hanninen, Merja Hallikaimen, Kari Alhainen, Hilkka Soininen, Jaakko Tuomilehto and Aulikki Nissimen. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal population based study. BMJ 2001; 322:1447-1451.
23. Wolozin B, Wellman W, Rousseau P, Celesia G.G and Siegel G. Decreased prevalence of Alzheimer's Disease associated with 3- hydroxy-3methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol.2000;57(10):1439-43.
24. Jick H, Zornberg G. L, Jick S. S, Seshadri S, and Drachman D. A. Statins and the risk of DementiaLancet, 2000. 356(9242): 1627-31.
25. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, Wormstall H, Hartmann T, Schulz JB. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002 Sep;52(3):346-50.
26. Ott A, Stolk RP, Van Harskamp F, Pols HA, Holfman A & Breteler M. M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53:1937-1942.
27. Peila R. Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu- Asia aging study. Diabetes 2002; 51: 1256-1262.
28. Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1993;41:1305-1312.
29. Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol A Biol Med Sci 1993;48:M117-M121.
30. Friedland RP, Fritish T, Smyth KA, et al.Patients with Alzheimer's disease have reduced activities in midlife compared with health control group members. Proc. Natl. Acad. Sci. USA 2001; 98 : 3440-45.
31. Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol. 2001 Mar;38(3):498-504.
32. Jeandel C, Nicolas MB, Nabet- Belleville F et al. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 1989; 35 : 275-82.
33. Morris MC, Evans DA, Bienias JL et al.Dietary intake of antioxidant nutrients and the risk of incident Alzheimer's disease in a biracial community study. JAMA 2002; 287 : 3230-37.
34. Masaki KH, Losonczy KG, Izmirlian G et al.Association of Vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 20000; 54 : 1265-72.
35. Kalimijn S, Launer LJ, Ott A et al. Dietary fat intake and the risk of incident dementia in the rotterdam study. Ann. Neurol 1997; 42 : 776-82.